Citation: | WU Ming-hao, LIU Jian, HU Gui-cai, GAO Yu, ZHANG Bao-hong, ZHOU Jin, ZHAO Ya-juan. Effects of liraglutide on 8-OHdG, MDA and SOD of kidney in insulin resistance rats[J]. Journal of Clinical Nephrology, 2017, 17(3): 177-180. DOI: 10.3969/j.issn.1671-2390.2017.03.010 |
[1] |
Liao MT1, Sung CC, Hung KC. Insulin resistance in patients with chronic kidney disease[J]. J Biomed Biotechnol, 2012, 8(7): 691369.
|
[2] |
Sahoo S, Meijles DN, Pagano PJ. NADPH oxidases: key modulators in aging and age-related cardiovascular diseases?[J]. Clin Sci (Lond), 2016, 130(5): 317-335.
|
[3] |
Nistala R, Whaley-Connell A. Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome;role for angiotensin II[J]. Mol Cell Endocrinol, 2013, 378(1-2): 53-58.
|
[4] |
Nagaraj M,Mandakini Pl,Jeffrey L,et al.RhoA/Rho kinase mediates TGF-β1-induced kidney myofibroblast activation through Poldip2/Nox4-derived reactive oxygen species[J]. Am J Physiol Renal Physiol, 2014, 307(2): F159-F171.
|
[5] |
Nikooyeh B, Neyestani TR.Oxidative stress, type 2 diabetes and vitamin D: past, present and future[J]. Diabetes Metab Res Rev, 2016, 32(3): 260-267.
|
[6] |
Faria AM, Papadimitriou A, silva KC, et al. Uncoupling endo-thelial nitric oxide synthase is ameliorated by green tea in ex-perimental diabetes by re-establishing tetrahydrobiopterin lev-els[J].Diabetes, 2012, 61: 1838-1847.
|
[7] |
Ock CY, Kim EH, Choi DJ, et al. 8-Hydroxydeoxyguanosine: Not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases[J]. World J Gastroenterol, 2012, 18(4): 302-308.
|
[8] |
Poljsak B, Suput D, Milisav I. Achieving the Balance between ROS and Antioxidants: When to Use the Synthetic Antioxidants[J]. Oxid Med Cell Longev, 2013, 4(29): 956792.
|
[9] |
Batinic-Haberle I, Tovmasyan A, Roberts ER, et al. SOD Therapeutics: Latest Insights into Their Structure-Activity Relationships and Impact on the Cellular Redox-Based Signaling Pathways [J]. Antioxid Redox Signal, 2014, 20(15): 2372-2415.
|
[10] |
刘剑, 吴明昊, 高宇. 肠促胰素分泌分子机制的研究进展[J]. 世界华人消化杂志, 2015, 23(16): 2582-2587.
|
[11] |
Skov J. Effects of GLP-1 in the Kidney[J].Rev Endocr Metab Disord, 2014, 15(3): 197-207.
|
[12] |
von Scholten BJ, Hansen TW, Goetze JP, et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA):long-term effect on kidney function in patients with type 2 diabetes[J]. J Diabetes Complications, 2015, 29(5): 670-674.
|
[13] |
Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells[J]. Atherosclerosis, 2012, 221(2): 375-382.
|
[14] |
Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases[J]. Metabolism, 2012, 61(10): 1422-1434.
|
[15] |
Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kineticsand suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes[J]. Diabetologia, 2011, 54(5): 1098-1108.
|